- Home
- CANG vs KMDA Comparison
CANG vs KMDA Comparison
Compare CANG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- KMDA
- Stock Information
- Founded
- CANG 2010
- KMDA 1990
- Country
- CANG China
- KMDA Israel
- Employees
- CANG N/A
- KMDA N/A
- Industry
- CANG Computer Software: Prepackaged Software
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- KMDA Health Care
- Exchange
- CANG Nasdaq
- KMDA Nasdaq
- Market Cap
- CANG 504.1M
- KMDA 442.1M
- IPO Year
- CANG 2018
- KMDA N/A
- Fundamental
- Price
- CANG $4.14
- KMDA $7.46
- Analyst Decision
- CANG
- KMDA Strong Buy
- Analyst Count
- CANG 0
- KMDA 2
- Target Price
- CANG N/A
- KMDA $14.50
- AVG Volume (30 Days)
- CANG 358.6K
- KMDA 342.2K
- Earning Date
- CANG 03-10-2025
- KMDA 03-05-2025
- Dividend Yield
- CANG N/A
- KMDA N/A
- EPS Growth
- CANG N/A
- KMDA 124.29
- EPS
- CANG 0.19
- KMDA 0.27
- Revenue
- CANG $38,020,222.00
- KMDA $158,380,000.00
- Revenue This Year
- CANG $253.48
- KMDA $15.37
- Revenue Next Year
- CANG N/A
- KMDA $8.58
- P/E Ratio
- CANG $22.60
- KMDA $28.13
- Revenue Growth
- CANG N/A
- KMDA 4.52
- 52 Week Low
- CANG $1.32
- KMDA $4.74
- 52 Week High
- CANG $9.66
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- CANG 38.49
- KMDA 52.89
- Support Level
- CANG $4.30
- KMDA $7.51
- Resistance Level
- CANG $5.22
- KMDA $8.35
- Average True Range (ATR)
- CANG 0.30
- KMDA 0.41
- MACD
- CANG -0.07
- KMDA -0.02
- Stochastic Oscillator
- CANG 3.57
- KMDA 33.20
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.